ResMed Inc. (RMD)
The In Plan Roth 401(k) Conversion That Saves a $400,000 Earner $58,000 in Future RMD Taxes
Picture a 55-year-old earning $400,000 with $1.5 million in a traditional 401(k).
Is the Options Market Predicting a Spike in ResMed Stock?
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
Here's Why ResMed (RMD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
Resmed beats Q3 earnings and revenue estimates with strong margin gains, yet shares slip post earnings despite growth across key segments.
ResMed (RMD) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Wall Street's Insights Into Key Metrics Ahead of ResMed (RMD) Q3 Earnings
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Resmed's Q3 Earnings on Deck: What's in Store for the Stock?
RMD gears up for fiscal Q3 earnings with steady estimates, rising demand in sleep devices and AI-driven digital health tools poised to shape results.
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Continue to Hold Resmed Stock in Your Portfolio?
RMD's growth strategy, rising device demand and solid finances support momentum, but macro pressures and stiff competition could test its outlook.
After Plunging 12.0% in 4 Weeks, Here's Why the Trend Might Reverse for ResMed (RMD)
ResMed (RMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ResMed (RMD) Upgraded to Buy: Here's What You Should Know
ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
